Please login to the form below

Not currently logged in

Excellence in Demonstrating Economic and Societal Value

Sponsored by

Back to Results


IMPACT - Building the Economic Case for Better Diabetes Control

by Sanofi

Summary of work

Diabetes costs the NHS around £10 billion per year with nearly 80% of these costs attributable to treating complications,1 which could potentially be reduced through improved blood glucose control.

Around 1/3 of people with diabetes in England are not achieving the QOF-defined benchmark of good control, an HbA1c below 59 mmol/mol (7.5%).2 Therapy escalations currently take place at higher HbA1c thresholds than recommended by NICE and data indicates that the UK has higher blood glucose levels (HbA1c 9.8%) at the point of insulin initiation than other developed countries.3

Sanofi developed a three-stage ‘Impact of Diabetes’ Programme in collaboration with Diabetes UK and JDRF. IMPACT 1 estimated the cost of diabetes to the NHS; IMPACT 2 modelled how improvements in blood glucose control could reduce clinical complications and costs of diabetes at a national level; IMPACT 3 provided a tool to support local commissioning decisions based on costs which may be avoided by improving blood glucose control.

The programme was supported by a wide range of tactics, including: posters and peer-reviewed publications; press releases; a parliamentary briefing meeting; editorial and advertorial and field team meetings. A number of clinicians have changed practice and redesigned services as a result.

Judges' comments

What was really impressive about this integrated project is that Sanofi successfully partnered with leading health economic groups. The ambitious, yet successful, programme was clearly articulated and coherent to resonate with stakeholders.

PMEA Awards 2020

Key dates

Entry deadline 27 August 2020
Extended entry deadline 3 September 2020*
*additional fee applies
Judging Day 1 October 2020
Company of the Year Interviews 22 October 2020
PMEA Event 25 November 2020